Actient to license and acquire products from UCB

Actient announces it has completed a transaction to license and acquire six pharmaceutical products from UCB.

The product set will form the basis of a commercial platform upon which Actient will continue to license and acquire strategic pharmaceutical assets.

Products in the transaction included: Edex (alprostadil for injection), Theo-24 (theophylline anhydrous), Semprex-D Capsules (acrivastine and pseudoephedrine hydrochloride), Levatol (penbutolol sulfate), Robaxin (methocarbamol tablets, USP) and Dilatrate-SR (isosorbide dinitrate).

The company plans to expand the senior leadership team and hire a number of employees in support of the expanded product portfolio associated with the acquisition.

“We are very pleased to add these products to our company as they represent important therapies for patients across the U.S.,” said Ed Fiorentino, CEO, Actient. “Going forward, we will continue to seek additional opportunities in specialty areas that allow us to extend our branded prescription product offering.”